Review





Similar Products

p63 antibody  (Novus Biologicals)
90
Novus Biologicals p63 antibody
( A ) Western blotting on lysates from NCI-H358 and NCI-H1299 cells following a cisplatin pulse, with the addition of dactolisib (1 µM), as indicated. ( B ) Quantification of effects of dactolisib upon cisplatin induced <t>p63</t> and p21 expression (n = 3, mean ± SD). ( C ) Western blotting on lysates from NCI-H358 cells, treated with P70S6K or control siRNA, as indicated, prior to and following a cisplatin pulse (n = 3, mean ± SD). ( D ) Apoptosis measured by propidium iodide staining for the sub-G1 population performed 72 hr following a cisplatin pulse with the addition of dactolisib (1 µM) as indicated (n = 3, mean ± SD). ( E ) Western blotting on lysates from A549 and NCI-H1573 cells, 48 hr following a cisplatin pulse, with the addition of dactolisib (1 µM), as indicated (n = 3, mean ± SD). ( F ) Western blotting across a second panel of lung adenocarcinoma cell lines. ( G ) Correlation between P70S6K phosphorylation and apoptosis, as measured by propidium iodide staining for the sub-G1 population, performed 72 hr following a cisplatin pulse (n = 3, mean ± SD). For all panels the statistical significance was determined by one-way ANOVA (***p<0.001, **p<0.01, *p<0.05).
P63 Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p63 antibody/product/Novus Biologicals
Average 90 stars, based on 1 article reviews
p63 antibody - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
antibody anti p63  (Novus Biologicals)
90
Novus Biologicals antibody anti p63
Figure 6. Response to dactolisib is dependent upon TP53 mutation status. (A) Western blotting on lysates from NCI-H358 and NCI-H1299 cells following a cisplatin pulse, with the addition of dactolisib (1 mM), as indicated. (B) Quantification of effects of dactolisib upon cisplatin induced <t>p63</t> and p21 expression (n = 3, mean ± SD). (C) Western blotting on lysates from NCI-H358 cells, treated with P70S6K or control siRNA, as indicated, prior to and following a cisplatin pulse (n = 3, mean ± SD). (D) Apoptosis measured by propidium iodide staining for the sub-G1 population performed 72 hr following a cisplatin pulse with the addition of dactolisib (1 mM) as indicated (n = 3, mean ± SD). (E) Western blotting on lysates from A549 and NCI- H1573 cells, 48 hr following a cisplatin pulse, with the addition of dactolisib (1 mM), as indicated (n = 3, mean ± SD). (F) Western blotting across a second panel of lung adenocarcinoma cell lines. (G) Correlation between P70S6K phosphorylation and apoptosis, as measured by propidium iodide staining for the sub-G1 population, performed 72 hr following a cisplatin pulse (n = 3, mean ± SD). For all panels the statistical significance was determined by one-way ANOVA (***p<0.001, **p<0.01, *p<0.05).
Antibody Anti P63, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibody anti p63/product/Novus Biologicals
Average 90 stars, based on 1 article reviews
antibody anti p63 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


( A ) Western blotting on lysates from NCI-H358 and NCI-H1299 cells following a cisplatin pulse, with the addition of dactolisib (1 µM), as indicated. ( B ) Quantification of effects of dactolisib upon cisplatin induced p63 and p21 expression (n = 3, mean ± SD). ( C ) Western blotting on lysates from NCI-H358 cells, treated with P70S6K or control siRNA, as indicated, prior to and following a cisplatin pulse (n = 3, mean ± SD). ( D ) Apoptosis measured by propidium iodide staining for the sub-G1 population performed 72 hr following a cisplatin pulse with the addition of dactolisib (1 µM) as indicated (n = 3, mean ± SD). ( E ) Western blotting on lysates from A549 and NCI-H1573 cells, 48 hr following a cisplatin pulse, with the addition of dactolisib (1 µM), as indicated (n = 3, mean ± SD). ( F ) Western blotting across a second panel of lung adenocarcinoma cell lines. ( G ) Correlation between P70S6K phosphorylation and apoptosis, as measured by propidium iodide staining for the sub-G1 population, performed 72 hr following a cisplatin pulse (n = 3, mean ± SD). For all panels the statistical significance was determined by one-way ANOVA (***p<0.001, **p<0.01, *p<0.05).

Journal: eLife

Article Title: Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma

doi: 10.7554/eLife.53367

Figure Lengend Snippet: ( A ) Western blotting on lysates from NCI-H358 and NCI-H1299 cells following a cisplatin pulse, with the addition of dactolisib (1 µM), as indicated. ( B ) Quantification of effects of dactolisib upon cisplatin induced p63 and p21 expression (n = 3, mean ± SD). ( C ) Western blotting on lysates from NCI-H358 cells, treated with P70S6K or control siRNA, as indicated, prior to and following a cisplatin pulse (n = 3, mean ± SD). ( D ) Apoptosis measured by propidium iodide staining for the sub-G1 population performed 72 hr following a cisplatin pulse with the addition of dactolisib (1 µM) as indicated (n = 3, mean ± SD). ( E ) Western blotting on lysates from A549 and NCI-H1573 cells, 48 hr following a cisplatin pulse, with the addition of dactolisib (1 µM), as indicated (n = 3, mean ± SD). ( F ) Western blotting across a second panel of lung adenocarcinoma cell lines. ( G ) Correlation between P70S6K phosphorylation and apoptosis, as measured by propidium iodide staining for the sub-G1 population, performed 72 hr following a cisplatin pulse (n = 3, mean ± SD). For all panels the statistical significance was determined by one-way ANOVA (***p<0.001, **p<0.01, *p<0.05).

Article Snippet: The p63 antibody (NB100-691) was from Novus Biologicals (CO, USA).

Techniques: Western Blot, Expressing, Control, Staining, Phospho-proteomics

Journal: eLife

Article Title: Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma

doi: 10.7554/eLife.53367

Figure Lengend Snippet:

Article Snippet: The p63 antibody (NB100-691) was from Novus Biologicals (CO, USA).

Techniques: Modification, Transfection, Construct, Plasmid Preparation, Proliferation Assay, Software, Membrane, Control

Figure 6. Response to dactolisib is dependent upon TP53 mutation status. (A) Western blotting on lysates from NCI-H358 and NCI-H1299 cells following a cisplatin pulse, with the addition of dactolisib (1 mM), as indicated. (B) Quantification of effects of dactolisib upon cisplatin induced p63 and p21 expression (n = 3, mean ± SD). (C) Western blotting on lysates from NCI-H358 cells, treated with P70S6K or control siRNA, as indicated, prior to and following a cisplatin pulse (n = 3, mean ± SD). (D) Apoptosis measured by propidium iodide staining for the sub-G1 population performed 72 hr following a cisplatin pulse with the addition of dactolisib (1 mM) as indicated (n = 3, mean ± SD). (E) Western blotting on lysates from A549 and NCI- H1573 cells, 48 hr following a cisplatin pulse, with the addition of dactolisib (1 mM), as indicated (n = 3, mean ± SD). (F) Western blotting across a second panel of lung adenocarcinoma cell lines. (G) Correlation between P70S6K phosphorylation and apoptosis, as measured by propidium iodide staining for the sub-G1 population, performed 72 hr following a cisplatin pulse (n = 3, mean ± SD). For all panels the statistical significance was determined by one-way ANOVA (***p<0.001, **p<0.01, *p<0.05).

Journal: eLife

Article Title: Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma

doi: 10.7554/elife.53367

Figure Lengend Snippet: Figure 6. Response to dactolisib is dependent upon TP53 mutation status. (A) Western blotting on lysates from NCI-H358 and NCI-H1299 cells following a cisplatin pulse, with the addition of dactolisib (1 mM), as indicated. (B) Quantification of effects of dactolisib upon cisplatin induced p63 and p21 expression (n = 3, mean ± SD). (C) Western blotting on lysates from NCI-H358 cells, treated with P70S6K or control siRNA, as indicated, prior to and following a cisplatin pulse (n = 3, mean ± SD). (D) Apoptosis measured by propidium iodide staining for the sub-G1 population performed 72 hr following a cisplatin pulse with the addition of dactolisib (1 mM) as indicated (n = 3, mean ± SD). (E) Western blotting on lysates from A549 and NCI- H1573 cells, 48 hr following a cisplatin pulse, with the addition of dactolisib (1 mM), as indicated (n = 3, mean ± SD). (F) Western blotting across a second panel of lung adenocarcinoma cell lines. (G) Correlation between P70S6K phosphorylation and apoptosis, as measured by propidium iodide staining for the sub-G1 population, performed 72 hr following a cisplatin pulse (n = 3, mean ± SD). For all panels the statistical significance was determined by one-way ANOVA (***p<0.001, **p<0.01, *p<0.05).

Article Snippet: DOI: https://doi.org/10.7554/eLife.53367 17 of 25 Continued Reagent type (species) or resource Designation Source or reference Identifiers Additional information Antibody Anti-p70 S6 Kinase (rabbit monoclonal) Cell Signaling Technology #2708, RRID:AB_390722 WB (1:1000), IHC (1:600) Antibody Anti-phospho-p70 S6 Kinase (Thr389) (rabbit monoclonal) Cell Signaling Technology #9205, RRID:AB_330945 WB (1:1000) Antibody Anti-p21 Waf1/Cip1 (rabbit monoclonal) Cell Signaling Technology #2947, RRID:AB_823586 WB (1:1000) Antibody Anti-cleaved Caspase-3 (Asp175) (rabbit monoclonal) Cell Signaling Technology #9661, RRID:AB_2341188 WB (1:1000) Antibody Anti-cleaved Caspase-7 (Asp198) (rabbit monoclonal) Cell Signaling Technology #9491, RRID:AB_2068144 WB (1:1000) Antibody Anti-p53 (mouse monoclonal) Santa Cruz Biotechnology sc-126, RRID:AB_628082 WB (1:200) Antibody Anti-p63 (mouse monoclonal) Novus Biologicals NB100-691, RRID:AB_10002770 WB (1:1000) Antibody Anti-b-Actin (mouse monoclonal) Sigma Aldrich AC-15, RRID:AB_476692 WB (1:5000) Transfected construct (human) mVenus-hGeminin (1/110) (plasmid) Sakaue-Sawano et al., 2008 Transfected construct (human) mCherry-hCdt1 (30/120) (plasmid) Sakaue-Sawano et al., 2008 Chemical compound, drug NVP-BEZ235 Selleck Chem S1009 Chemical compound, drug MK-2206 2HCl Selleck Chem S1078 Chemical compound, drug S3I-201 Selleck Chem S1155 Chemical compound, drug U0126-EtOH Selleck Chem S1102 Chemical compound, drug SC75741 Selleck Chem S7273 Chemical compound, drug RNaseA Life Technologies AM2270 Chemical compound, drug Propidium iodide Sigma-Aldrich P4170 Chemical compound, drug CellTiter96 AQueous Non-Radioactive Cell Proliferation Assay Promega G5421 Chemical compound, drug Cisplatin Hospira Australia 88S035 Commercial assay or kit DNA Damage/Genotoxicity Magnetic Bead Panel (7-plex) Merck Millipore 48-621MAG MAGPIX assay, detects ATR (total), Chk1 (Ser345), Chk2 (Thr68), H2A.X (Ser139), MDM2 (total), p21 (total), p53 (Ser15) Commercial assay or kit TGFb Signaling Pathway Magnetic Bead Kit (6-plex) Merck Millipore 48-614MAG MAGPIX assay, detects Akt (Ser473), ERK (Thr185/Tyr187), Smad2 (Ser465/Ser467), Smad3 (Ser423/Ser425), Smad4 (total), TGFbRII (total) Continued on next page Hastings et al. eLife 2020;9:e53367.

Techniques: Mutagenesis, Western Blot, Expressing, Control, Staining, Phospho-proteomics